Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
CHRS POWR Grades
- Value is the dimension where CHRS ranks best; there it ranks ahead of 87.36% of US stocks.
- CHRS's strongest trending metric is Growth; it's been moving up over the last 179 days.
- CHRS's current lowest rank is in the Sentiment metric (where it is better than 3.74% of US stocks).
CHRS Stock Summary
- With a one year PEG ratio of 1.28, Coherus BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 6.36% of US stocks.
- Over the past twelve months, CHRS has reported earnings growth of -268.38%, putting it ahead of merely 7.23% of US stocks in our set.
- Revenue growth over the past 12 months for Coherus BioSciences Inc comes in at -31.37%, a number that bests only 5.34% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Coherus BioSciences Inc, a group of peers worth examining would be AGLE, MCRB, CRIS, VYGR, and SURF.
- CHRS's SEC filings can be seen here. And to visit Coherus BioSciences Inc's official web site, go to www.coherus.com.
CHRS Valuation Summary
- CHRS's price/sales ratio is 3.1; this is 18.42% lower than that of the median Healthcare stock.
- Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.
- Over the past 83 months, CHRS's price/sales ratio has gone down 12.5.
Below are key valuation metrics over time for CHRS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CHRS | 2021-08-31 | 3.1 | 7.8 | -7.4 | -9.3 |
CHRS | 2021-08-30 | 3.1 | 7.8 | -7.3 | -9.2 |
CHRS | 2021-08-27 | 3.1 | 7.7 | -7.3 | -9.1 |
CHRS | 2021-08-26 | 3.1 | 7.7 | -7.3 | -9.2 |
CHRS | 2021-08-25 | 3.0 | 7.6 | -7.2 | -9.0 |
CHRS | 2021-08-24 | 3.0 | 7.5 | -7.1 | -8.9 |
CHRS Growth Metrics
- Its 4 year price growth rate is now at -13.23%.
- Its year over year net cashflow from operations growth rate is now at 43.74%.
- The 3 year price growth rate now stands at -16.15%.

The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 326.551 | -37.432 | -287.1 |
2021-09-30 | 363.599 | 48.014 | -231.667 |
2021-06-30 | 394.647 | 81.656 | -165.206 |
2021-03-31 | 442.678 | 142.035 | -76.275 |
2020-12-31 | 475.824 | 154.145 | 132.244 |
2020-09-30 | 489.261 | 138.731 | 161.763 |
CHRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CHRS has a Quality Grade of B, ranking ahead of 82.07% of graded US stocks.
- CHRS's asset turnover comes in at 0.513 -- ranking 78th of 682 Pharmaceutical Products stocks.
- CPRX, XTNT, and VIVO are the stocks whose asset turnover ratios are most correlated with CHRS.
The table below shows CHRS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.513 | 0.886 | -0.228 |
2021-03-31 | 0.572 | 0.913 | -0.075 |
2020-12-31 | 0.664 | 0.921 | 0.250 |
2020-09-30 | 0.803 | 0.931 | 0.332 |
2020-06-30 | 0.995 | 0.936 | 0.477 |
2020-03-31 | 1.206 | 0.950 | 0.576 |
CHRS Price Target
For more insight on analysts targets of CHRS, see our CHRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $25.71 | Average Broker Recommendation | 1.57 (Moderate Buy) |
CHRS Stock Price Chart Interactive Chart >
CHRS Price/Volume Stats
Current price | $7.54 | 52-week high | $19.32 |
Prev. close | $7.66 | 52-week low | $7.24 |
Day low | $7.36 | Volume | 867,986 |
Day high | $7.81 | Avg. volume | 941,963 |
50-day MA | $10.21 | Dividend yield | N/A |
200-day MA | $14.17 | Market Cap | 583.77M |
Coherus BioSciences, Inc. (CHRS) Company Bio
Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.
Latest CHRS News From Around the Web
Below are the latest news stories about Coherus BioSciences Inc that investors may wish to consider to help them evaluate CHRS as an investment opportunity.
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2021 Results - Earnings Call TranscriptCoherus BioSciences, Inc. (CHRS) Q4 2021 Earnings Conference Call February 17, 2022 5:00 PM ET Company Participants Denny Lanfear - President, Chief Executive Officer and Chairman McDavid Stilwell - Chief Financial Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Conference Call Participants Salim Syed -... |
Coherus BioSciences'' Q4 Sales Fall 34% On Lower Udenyca Volume, PricesCoherus BioSciences Inc''s (NASDAQ: CHRS ) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts. The company posted an adjusted EPS … Full story available on Benzinga.com |
Coherus BioSciences Non-GAAP EPS of -$0.46 beats by $0.08, revenue of $73.37M misses by $9.24MCoherus BioSciences press release (NASDAQ:CHRS): Q4 Non-GAAP EPS of -$0.46 beats by $0.08. Revenue of $73.37M (-33.6% Y/Y) misses by $9.24M. Cash and cash equivalents were $417.2 million as of December 31, 2021, compared to $541.2 million as of December 31, 2020. 2022 Guidance: Coherus projects combined R&D and SG&A expenses... |
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results– YUSIMRY ™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI ™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA ® on-body injector and additional toripalimab indications – – UDENYCA ® delivered net sales of $73 million in 4Q 2021; $327 million in FY 2021 – – Conference call and webcast today at 5:00 p.m. ET – |
Coherus BioSciences (CHRS) Q4 2021 Earnings Call TranscriptCHRS earnings call for the period ending December 31, 2021. |
CHRS Price Returns
1-mo | -18.75% |
3-mo | -35.72% |
6-mo | -58.95% |
1-year | -42.75% |
3-year | -60.67% |
5-year | -62.77% |
YTD | -52.76% |
2021 | -8.17% |
2020 | -3.47% |
2019 | 98.95% |
2018 | 2.84% |
2017 | -68.74% |
Continue Researching CHRS
Want to do more research on Coherus BioSciences Inc's stock and its price? Try the links below:Coherus BioSciences Inc (CHRS) Stock Price | Nasdaq
Coherus BioSciences Inc (CHRS) Stock Quote, History and News - Yahoo Finance
Coherus BioSciences Inc (CHRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...